The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy

G. Absenger, L. Benhaim, J. Szkandera, W. Zhang, D. Yang, M. J. Labonte, M. Pichler, M. Stotz, H. Samonigg, W. Renner, A. Gerger, H. J. Lenz

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

16 Citations (Scopus)

Résumé

Recent evidence indicates a potential prognostic and predictive value for germline polymorphisms in genes involved in cell cycle control. We investigated the effect of cyclin D1 (CCND1) rs9344 G>A in stage II/III colon cancer patients and validated the findings in an independent study cohort. For evaluation and validation set, a total of 264 and 234 patients were included. Patients treated with 5-fluorouracil-based chemotherapy, carrying the CCND1 rs9344 A/A genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16-5.29; P=0.019). There was no significant association between CCND1 rs9344 G>A and TTR in patients with curative surgery alone. In the validation set, the A allele of CCND1 rs9344 G>A remained significantly associated with decreased TTR in univariate and multivariate analyses (HR 1.94; 95% CI 1.05-3.58; P=0.035). CCND1 rs9344 G>A may be a predictive and/or prognostic biomarker in stage II/III colon cancer patients, however, prospective trials are warranted to confirm our findings.

langue originaleAnglais
Pages (de - à)130-134
Nombre de pages5
journalPharmacogenomics Journal
Volume14
Numéro de publication2
Les DOIs
étatPublié - 1 janv. 2014
Modification externeOui

Contient cette citation